U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104162) titled 'A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment' on July 29.
Brief Summary: A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Bacterial Infections
Intervention:
DRUG: Cefiderocol/Xeruborbactam
A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qpex Biopharma, Inc.
Disclaimer: Cu...